Nov 3 (Reuters) - Intercept Pharmaceuticals Inc
* Intercept pharmaceuticals inc- eu marketing approval decision for ocaliva anticipated by year end 2016
* Intercept pharmaceuticals inc- eu launch of ocaliva anticipated in early 2017
* Intercept pharmaceuticals reports third quarter 2016 financial results and provides business update
* Q3 sales $4.7 million versus i/b/e/s view $4.8 million Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.